Advanced Gardisil: Merck (with Qiagen) tests cervical cancer waters in Rwanda

 
• By Francesca Bruce
  
Generate a summary of this article
Listen to this article
Beta

Merck & Co's HPV vaccine Gardasil and Qiagen's HPV DNA tests are at the centre of Africa's first integrated cervical cancer prevention campaign that incorporates both vaccination and screening on a national level, launched this week by the Rwandan government. The programme, which Rwanda described as a world first, will show that new technology can be successfully introduced to developing countries and then other countries will likely follow suit, Rwanda's permanent secretary for the health ministry, Dr Agnes Binagwaho, told Scrip.

Merck & Co's HPV vaccine Gardasil and Qiagen's HPV DNA tests are at the centre of Africa's first integrated cervical cancer prevention campaign that incorporates both vaccination and screening on a national level, launched this week by the Rwandan government. The programme, which Rwanda described as a world first, will show that new technology can be successfully introduced to developing countries and then other countries will likely follow suit, Rwanda's permanent secretary for the health ministry, Dr Agnes Binagwaho, told Scrip.

For Merck, too, the Rwandan programme provides a form of demonstration project and an opportunity to garner data that will...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

 
• By Xu Hu

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

Allarity Hopes To Breathe New Life Into Ixempra In Breast Cancer

The US precision medicine company hopes its drug response predictor technology will enhance responses to the chemotherapy Ixempra on the basis of promising data from a handful of breast cancer patients in a Phase II trial, marking a positive turn in its journey to date.  

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.